\babel@toc {english}{}\relax 
\contentsline {part}{I\hspace {1em}Notes}{4}{part.1}%
\contentsline {chapter}{\numberline {1}Introduction}{5}{chapter.1}%
\contentsline {section}{\numberline {1.1}Genetics vs Genomics}{5}{section.1.1}%
\contentsline {subsection}{\numberline {1.1.1}Genetics}{5}{subsection.1.1.1}%
\contentsline {subsection}{\numberline {1.1.2}Genomics}{5}{subsection.1.1.2}%
\contentsline {subsection}{\numberline {1.1.3}Differences}{5}{subsection.1.1.3}%
\contentsline {subsection}{\numberline {1.1.4}Role of computational biology}{5}{subsection.1.1.4}%
\contentsline {section}{\numberline {1.2}Human Genomics - the Basis}{6}{section.1.2}%
\contentsline {subsection}{\numberline {1.2.1}Genetic Make-Up}{6}{subsection.1.2.1}%
\contentsline {subsubsection}{\numberline {1.2.1.1}Single nucleotide polymorphisms}{6}{subsubsection.1.2.1.1}%
\contentsline {subsubsection}{\numberline {1.2.1.2}Copy number variants}{6}{subsubsection.1.2.1.2}%
\contentsline {subsection}{\numberline {1.2.2}Inherited variants' relevance}{6}{subsection.1.2.2}%
\contentsline {paragraph}{\numberline {1.2.2.0.1}Penetrance}{6}{paragraph.1.2.2.0.1}%
\contentsline {paragraph}{\numberline {1.2.2.0.2}Allele frequency}{7}{paragraph.1.2.2.0.2}%
\contentsline {subsection}{\numberline {1.2.3}Differences in Genetic Make-Up, an example}{7}{subsection.1.2.3}%
\contentsline {subsection}{\numberline {1.2.4}Acquired DNA aberrations}{7}{subsection.1.2.4}%
\contentsline {subsubsection}{\numberline {1.2.4.1}Types of acquired DNA aberrations}{7}{subsubsection.1.2.4.1}%
\contentsline {paragraph}{\numberline {1.2.4.1.1}Translocation}{7}{paragraph.1.2.4.1.1}%
\contentsline {paragraph}{\numberline {1.2.4.1.2}Inversion}{7}{paragraph.1.2.4.1.2}%
\contentsline {paragraph}{\numberline {1.2.4.1.3}Copy number changes}{8}{paragraph.1.2.4.1.3}%
\contentsline {paragraph}{\numberline {1.2.4.1.4}Chromoplexy}{8}{paragraph.1.2.4.1.4}%
\contentsline {paragraph}{\numberline {1.2.4.1.5}Chromothripsis}{8}{paragraph.1.2.4.1.5}%
\contentsline {paragraph}{\numberline {1.2.4.1.6}Kataegis}{8}{paragraph.1.2.4.1.6}%
\contentsline {section}{\numberline {1.3}Experimental techniques to detect variants/aberrations}{8}{section.1.3}%
\contentsline {subsection}{\numberline {1.3.1}Cariotyping}{8}{subsection.1.3.1}%
\contentsline {section}{\numberline {1.4}Sequence capture for cancer genomics}{8}{section.1.4}%
\contentsline {subsection}{\numberline {1.4.1}Single End (SE) and Paired End (PE) reads}{8}{subsection.1.4.1}%
\contentsline {part}{II\hspace {1em}Papers}{10}{part.2}%
\contentsline {chapter}{\numberline {2}Role of non-coding sequence variants in cancer}{11}{chapter.2}%
\contentsline {section}{\numberline {2.1}Abstract}{11}{section.2.1}%
\contentsline {subsection}{\numberline {2.1.1}Introduction}{11}{subsection.2.1.1}%
\contentsline {section}{\numberline {2.2}Genomic sequence variants}{11}{section.2.2}%
\contentsline {section}{\numberline {2.3}Non-coding element annotation}{12}{section.2.3}%
\contentsline {subsection}{\numberline {2.3.1}Cis regulatory regions}{12}{subsection.2.3.1}%
\contentsline {subsection}{\numberline {2.3.2}Distal regulatory elements}{12}{subsection.2.3.2}%
\contentsline {subsection}{\numberline {2.3.3}RNA-seq}{12}{subsection.2.3.3}%
\contentsline {subsection}{\numberline {2.3.4}Transcribed pseudogenes}{12}{subsection.2.3.4}%
\contentsline {subsection}{\numberline {2.3.5}Evolutionary conservation}{13}{subsection.2.3.5}%
\contentsline {section}{\numberline {2.4}Roles for somatic variants in cancer}{13}{section.2.4}%
\contentsline {subsection}{\numberline {2.4.1}Gain of TF-binding sites}{13}{subsection.2.4.1}%
\contentsline {subsection}{\numberline {2.4.2}Fusion events due to genomic rearrangements}{13}{subsection.2.4.2}%
\contentsline {subsection}{\numberline {2.4.3}ncRNAs and their binding sites}{13}{subsection.2.4.3}%
\contentsline {subsection}{\numberline {2.4.4}Role of pseudogenes in modulating the expression of a parental gene}{14}{subsection.2.4.4}%
\contentsline {section}{\numberline {2.5}Roles for germline variants in cancer}{14}{section.2.5}%
\contentsline {subsection}{\numberline {2.5.1}Promoter mutations}{14}{subsection.2.5.1}%
\contentsline {subsection}{\numberline {2.5.2}SNPs in enhancers}{14}{subsection.2.5.2}%
\contentsline {subsection}{\numberline {2.5.3}Variants in introns}{14}{subsection.2.5.3}%
\contentsline {subsection}{\numberline {2.5.4}SNPs in ncRNA and their binding sites}{14}{subsection.2.5.4}%
\contentsline {subsection}{\numberline {2.5.5}Others}{14}{subsection.2.5.5}%
\contentsline {section}{\numberline {2.6}Interplay between germline and somatic variants}{14}{section.2.6}%
\contentsline {section}{\numberline {2.7}Computational methods for identifying variants}{15}{section.2.7}%
\contentsline {section}{\numberline {2.8}Experimental approaches for functional validation}{15}{section.2.8}%
\contentsline {chapter}{\numberline {3}Advances in understanding cancer genomics through second-generation sequencing}{17}{chapter.3}%
\contentsline {section}{\numberline {3.1}Abstract}{17}{section.3.1}%
\contentsline {subsection}{\numberline {3.1.1}Introduction}{17}{subsection.3.1.1}%
\contentsline {section}{\numberline {3.2}Cancer-specific consideration}{17}{section.3.2}%
\contentsline {subsection}{\numberline {3.2.1}Characteristics of cancer samples for genomic analysis}{18}{subsection.3.2.1}%
\contentsline {subsection}{\numberline {3.2.2}Structural variability of cancer genomes}{18}{subsection.3.2.2}%
\contentsline {section}{\numberline {3.3}Experimental approaches}{18}{section.3.3}%
\contentsline {subsection}{\numberline {3.3.1}Whole genome sequencing}{18}{subsection.3.3.1}%
\contentsline {subsection}{\numberline {3.3.2}Exome sequencing}{18}{subsection.3.3.2}%
\contentsline {subsection}{\numberline {3.3.3}Transcriptome sequencing}{19}{subsection.3.3.3}%
\contentsline {section}{\numberline {3.4}Detecting classes of genome alterations}{19}{section.3.4}%
\contentsline {subsection}{\numberline {3.4.1}Somatic nucleotide substitutions and small insertion and deletion mutations}{19}{subsection.3.4.1}%
\contentsline {subsection}{\numberline {3.4.2}Copy number}{19}{subsection.3.4.2}%
\contentsline {subsection}{\numberline {3.4.3}Chromosomal rearrangements}{19}{subsection.3.4.3}%
\contentsline {subsection}{\numberline {3.4.4}Microbe-discovery methods}{20}{subsection.3.4.4}%
\contentsline {section}{\numberline {3.5}Computational issues}{20}{section.3.5}%
\contentsline {subsection}{\numberline {3.5.1}Alignment and assembly}{20}{subsection.3.5.1}%
\contentsline {subsection}{\numberline {3.5.2}mutations detection}{20}{subsection.3.5.2}%
\contentsline {subsection}{\numberline {3.5.3}Validation of mutation and rearrangement calls}{20}{subsection.3.5.3}%
\contentsline {chapter}{\numberline {4}Integrative genomics viewer}{22}{chapter.4}%
\contentsline {section}{\numberline {4.1}Introduction}{22}{section.4.1}%
\contentsline {chapter}{\numberline {5}Tumour heterogeneity and resistance to cancer therapies}{23}{chapter.5}%
\contentsline {section}{\numberline {5.1}Abstract}{23}{section.5.1}%
\contentsline {subsection}{\numberline {5.1.1}Introduction}{23}{subsection.5.1.1}%
\contentsline {section}{\numberline {5.2}Causes of intratumoral heterogeneity}{23}{section.5.2}%
\contentsline {subsection}{\numberline {5.2.1}Genomic instability}{23}{subsection.5.2.1}%
\contentsline {subsection}{\numberline {5.2.2}The clonal evolution and selection hypothesis}{24}{subsection.5.2.2}%
\contentsline {section}{\numberline {5.3}The spectrum of tumour heterogeneity}{24}{section.5.3}%
\contentsline {subsection}{\numberline {5.3.1}Spatial heterogeneity}{24}{subsection.5.3.1}%
\contentsline {subsubsection}{\numberline {5.3.1.1}Heterogeneity at a single disease site}{24}{subsubsection.5.3.1.1}%
\contentsline {subsubsection}{\numberline {5.3.1.2}Comparison of spatially distinct disease sites}{24}{subsubsection.5.3.1.2}%
\contentsline {subsection}{\numberline {5.3.2}Temporal heterogeneity}{25}{subsection.5.3.2}%
\contentsline {subsubsection}{\numberline {5.3.2.1}Genomic complexity might increase with exposure to targeted therapies}{25}{subsubsection.5.3.2.1}%
\contentsline {subsubsection}{\numberline {5.3.2.2}Longitudinal sampling provides insight into temporal heterogeneity}{25}{subsubsection.5.3.2.2}%
\contentsline {subsubsection}{\numberline {5.3.2.3}Residual drug-tolerant cells can foster temporal heterogeneity}{25}{subsubsection.5.3.2.3}%
\contentsline {section}{\numberline {5.4}Noninvasive monitoring of heterogeneity}{26}{section.5.4}%
\contentsline {subsection}{\numberline {5.4.1}Analysis of ctDNA}{26}{subsection.5.4.1}%
\contentsline {section}{\numberline {5.5}Overcoming heterogeneity}{26}{section.5.5}%
\contentsline {chapter}{\numberline {6}Unravelling the clonal hierarchy of somatic genomic aberrations}{28}{chapter.6}%
\contentsline {section}{\numberline {6.1}Introduction}{28}{section.6.1}%
\contentsline {subsection}{\numberline {6.1.1}Abstract}{28}{subsection.6.1.1}%
\contentsline {subsection}{\numberline {6.1.2}Background}{28}{subsection.6.1.2}%
\contentsline {section}{\numberline {6.2}Results}{29}{section.6.2}%
\contentsline {subsection}{\numberline {6.2.1}Clonality assessment of aberrations from sequencing reads}{29}{subsection.6.2.1}%
\contentsline {subsection}{\numberline {6.2.2}Inferring the order of mutations in a tumour sample}{29}{subsection.6.2.2}%
\contentsline {subsection}{\numberline {6.2.3}In silico and in situ experimental validation}{30}{subsection.6.2.3}%
\contentsline {subsection}{\numberline {6.2.4}Comparative analysis reveals different mechanisms of tumour deregulation}{30}{subsection.6.2.4}%
\contentsline {subsection}{\numberline {6.2.5}Clonal hierarchy of genomic aberrations}{31}{subsection.6.2.5}%
\contentsline {section}{\numberline {6.3}Materials and methods}{31}{section.6.3}%
\contentsline {subsection}{\numberline {6.3.1}CLONET pipeline}{31}{subsection.6.3.1}%
\contentsline {subsection}{\numberline {6.3.2}CLONET on exome and targeted sequencing data}{31}{subsection.6.3.2}%
\contentsline {subsection}{\numberline {6.3.3}Expected distribution of the allelic fraction of a genomic segment}{31}{subsection.6.3.3}%
\contentsline {subsection}{\numberline {6.3.4}Estimated proportion of neutral reads for a genomic segment}{32}{subsection.6.3.4}%
\contentsline {subsection}{\numberline {6.3.5}From neutral to non-aberrant reads}{32}{subsection.6.3.5}%
\contentsline {subsection}{\numberline {6.3.6}From aberrant reads to aberrant cells}{32}{subsection.6.3.6}%
\contentsline {subsection}{\numberline {6.3.7}Uncertainty assessment and its propagation to clonality estimates}{33}{subsection.6.3.7}%
\contentsline {subsection}{\numberline {6.3.8}Clonality of bi-allelic deletion}{33}{subsection.6.3.8}%
\contentsline {chapter}{\numberline {7}TPES: timor purity estimation from SNVs}{34}{chapter.7}%
\contentsline {section}{\numberline {7.1}Abstract}{34}{section.7.1}%
\contentsline {subsection}{\numberline {7.1.1}Introduction}{34}{subsection.7.1.1}%
\contentsline {section}{\numberline {7.2}Materials and methods}{34}{section.7.2}%
\contentsline {chapter}{\numberline {8}SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines}{36}{chapter.8}%
\contentsline {section}{\numberline {8.1}Abstract}{36}{section.8.1}%
\contentsline {subsection}{\numberline {8.1.1}Introduction}{36}{subsection.8.1.1}%
\contentsline {section}{\numberline {8.2}Material and methods}{36}{section.8.2}%
\contentsline {subsection}{\numberline {8.2.1}Genotype distance}{36}{subsection.8.2.1}%
\contentsline {subsection}{\numberline {8.2.2}SNP panel selection procedure}{37}{subsection.8.2.2}%
\contentsline {subsection}{\numberline {8.2.3}SPIA probabilistic test on cell line genotype distance}{37}{subsection.8.2.3}%
